RCT: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial – The Lancet

Commentary on Twitter

Phase 3 trial suggests #cemiplimab could be used as new first-line monotherapy option for patients with advanced non-small-cell #lungcancer with PD-L1 of at least 50%—it improved overall & progression-free survival compared with chemotherapy. Read https://t.co/O06Of6wx07 pic.twitter.com/KtQ24lEoR5

— The Lancet (@TheLancet) February 17, 2021